Pictet Asset Management
CTMX icon

Pictet Asset Management’s CytomX Therapeutics CTMX Stock Holding History

Pictet Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.3K Hold
16,606
– – ﹤0.01% 2121
2026
Q1 		$78K Buy
+16,606
New +$84.3K ﹤0.01% 2064

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Pictet Asset Management's CTMX Position: Q2 2026 in Review

Pictet Asset Management held its CytomX Therapeutics (CTMX) position steady in Q2 2026 at 16,606 shares worth $62.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2121.

Pictet Asset Management first reported a position in CTMX in Q1 2026 and has held it in 2 quarters since. The position peaked at $78K in Q1 2026. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Pictet Asset Management held 16,606 shares of CytomX Therapeutics worth $62.3K as of Q2 2026.
  • Pictet Asset Management left its CytomX Therapeutics share count unchanged in Q2 2026.
  • CytomX Therapeutics made up ﹤0.01% of Pictet Asset Management's portfolio in Q2 2026, its #2121 holding.
  • Pictet Asset Management first reported a position in CytomX Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Pictet Asset Management's CytomX Therapeutics position peaked at $78K in Q1 2026.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.